SCHEMBL5897376

SCHEMBL5897376

Cc1cccc(-c2ccc(/C=C(\NC(=O)c3ccccc3)C(=O)O)o2)c1C

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.47
MAPK1 P28482 7/20 0.47
ALDH1A1 P00352 8/20 0.47
MITF O75030 5/20 0.46
HTT P42858 2/20 0.46
NPSR1 Q6W5P4 1/20 0.46
LMNA P02545 4/20 0.46
SMN1; SMN2 Q16637 4/20 0.45
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
POLB P06746 2/20 0.44
HPGD P15428 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
GAA P10253 3/20 0.44
KDM4E B2RXH2 3/20 0.43
RAD52 P43351 1/20 0.43
APAF1 O14727 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5897381 1.00 MAPT (0.47) MAPTMAPK1ALDH1A1MITFHTT
SCHEMBL5897385 1.00 MAPT (0.47) MAPTMAPK1ALDH1A1MITFHTT
SCHEMBL847396 0.92 MAPK1 (0.50) MAPTMAPK1ALDH1A1MITFHTT
SCHEMBL5894971 0.92 MAPK1 (0.50) MAPTMAPK1ALDH1A1MITFHTT
SCHEMBL5894979 0.92 MAPK1 (0.50) MAPTMAPK1ALDH1A1MITFHTT
SCHEMBL5896497 0.82 MAPT (0.62) MAPTMAPK1ALDH1A1MITFHTT
SCHEMBL5896376 0.82 MEN1 (0.51) MAPTMAPK1ALDH1A1MITFHTT
SCHEMBL5896357 0.82 MEN1 (0.51) MAPTMAPK1ALDH1A1MITFHTT
SCHEMBL5895328 0.82 MAPK1 (0.50) MAPTMAPK1ALDH1A1MITFHTT
SCHEMBL5896487 0.82 MAPT (0.62) MAPTMAPK1ALDH1A1MITFHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7041690-B2 Inhibitors of HCV NS5B polymerase PHARMACIA & UPJOHN COMPANY, LLC (US) 2006-05-09 US disclosed
US-20060004063-A1 Inhibitors of HCV NS5B polymerase PHARMACIA & UPJOHN COMPANY, LLC 2006-01-05 US disclosed
EP-1532128-A1 INHIBITORS OF HCV NS5B POLYMERASE Pharmacia & Upjohn Company LLC (US) 2005-05-25 EP disclosed
WO-2004002977-A1 INHIBITORS OF HCV NS5B POLYMERASE PHARMACIA & UPJOHN COMPANY LLC (US) 2004-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004063-A1 Inhibitors of HCV NS5B polymerase POLRMT, EIF5B, POLI MAPT 3589/4885MAPK1 2559/4885ALDH1A1 1400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.